Squillaro Tiziana, Peluso Gianfranco, Galderisi Umberto
Department of Experimental Medicine, Biotechnology and Molecular Biology Section, Second University of Naples, Naples, Italy.
Cell Transplant. 2016;25(5):829-48. doi: 10.3727/096368915X689622. Epub 2015 Sep 29.
In the last year, the promising features of mesenchymal stem cells (MSCs), including their regenerative properties and ability to differentiate into diverse cell lineages, have generated great interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases. Currently the most commonly used adult stem cells in regenerative medicine, MSCs, can be isolated from several tissues, exhibit a strong capacity for replication in vitro, and can differentiate into osteoblasts, chondrocytes, and adipocytes. However, heterogeneous procedures for isolating and cultivating MSCs among laboratories have prompted the International Society for Cellular Therapy (ISCT) to issue criteria for identifying unique populations of these cells. Consequently, the isolation of MSCs according to ISCT criteria has produced heterogeneous, nonclonal cultures of stromal cells containing stem cells with different multipotent properties, committed progenitors, and differentiated cells. Though the nature and functions of MSCs remain unclear, nonclonal stromal cultures obtained from bone marrow and other tissues currently serve as sources of putative MSCs for therapeutic purposes, and several findings underscore their effectiveness in treating different diseases. To date, 493 MSC-based clinical trials, either complete or ongoing, appear in the database of the US National Institutes of Health. In the present article, we provide a comprehensive review of MSC-based clinical trials conducted worldwide that scrutinizes biological properties of MSCs, elucidates recent clinical findings and clinical trial phases of investigation, highlights therapeutic effects of MSCs, and identifies principal criticisms of the use of these cells. In particular, we analyze clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.
在过去的一年里,间充质干细胞(MSC)展现出的诸多有前景的特性,包括其再生特性以及分化为多种细胞谱系的能力,引起了研究人员的极大兴趣,他们的工作为各种疾病的细胞疗法提供了引人入胜的观点。目前,MSC是再生医学中最常用的成体干细胞,可从多种组织中分离得到,在体外具有强大的复制能力,并且能分化为成骨细胞、软骨细胞和脂肪细胞。然而,各实验室在分离和培养MSC的过程存在差异,这促使国际细胞治疗协会(ISCT)发布了鉴定这些细胞独特群体的标准。因此,按照ISCT标准分离的MSC产生了异质性的、非克隆的基质细胞培养物,其中包含具有不同多能特性的干细胞、定向祖细胞和分化细胞。尽管MSC的本质和功能仍不明确,但从骨髓和其他组织获得的非克隆基质培养物目前作为假定的MSC来源用于治疗目的,并且一些研究结果强调了它们在治疗不同疾病方面的有效性。迄今为止,美国国立卫生研究院的数据库中出现了493项基于MSC的已完成或正在进行的临床试验。在本文中,我们对全球范围内开展的基于MSC的临床试验进行了全面综述,审视了MSC的生物学特性,阐明了近期的临床研究结果和临床试验阶段,突出了MSC的治疗效果,并指出了使用这些细胞的主要争议点。特别是,我们分析了使用MSC治疗代表性疾病的临床试验,包括血液系统疾病、移植物抗宿主病、器官移植、糖尿病、炎症性疾病以及肝脏、肾脏和肺部疾病,还有心血管疾病、骨与软骨疾病、神经疾病和自身免疫性疾病。